Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 5/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26100233 | 0.86 | KIF11 (0.47) | TRPV4KIF11LOXL2MRGPRX4NSD2 | |
| SCHEMBL30392176 | 0.86 | KIF11 (0.47) | TRPV4KIF11LOXL2MRGPRX4NSD2 | |
| SCHEMBL24146520 | 0.82 | RXRA (0.50) | TRPV4KIF11MRGPRX4ARP4HB | |
| SCHEMBL1037550 | 0.82 | TRPV4 (0.49) | TRPV4KIF11MRGPRX4ARP4HB | |
| SCHEMBL10298852 | 0.82 | TRPV4 (0.49) | TRPV4KIF11MRGPRX4ARP4HB | |
| SCHEMBL22193269 | 0.82 | TRPV4 (0.53) | TRPV4KIF11MRGPRX4ARP4HB | |
| SCHEMBL19478936 | 0.79 | TRPV4 (0.46) | TRPV4KIF11MRGPRX4AR | |
| SCHEMBL27737736 | 0.79 | TRPV4 (0.46) | TRPV4KIF11MRGPRX4ARP4HB | |
| SCHEMBL24177142 | 0.79 | TRPV4 (0.50) | TRPV4KIF11MRGPRX4AREPHX2 | |
| SCHEMBL1741664 | 0.78 | TRPV4 (0.45) | TRPV4KIF11MRGPRX4ARP4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704904-A1 | TETRAZINE-BASED TARGETING AGENTS FOR IN VIVO DELIVERY OF A PAYLOAD | Tambo, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025224085-A1 | COMPOUNDS CAPABLE OF ACTING ON S1R AS WELL AS ON SEH AND USES THEREOF | UNIVERSITAT DE BARCELONA (ES) | 2025-10-30 | — | — | WO | disclosed |
| EP-4618985-A1 | DUAL INHIBITORS OF SIGMA-1 RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE AND THEIR USE IN THE TREATMENT OF PAIN | Universitat De Barcelona (ES) | 2025-09-24 | — | — | EP | disclosed |
| US-20250186592-A1 | TETRAZINE CONJUGATES FOR IN VIVO TARGETED DELIVERY OF A PAYLOAD | TAMBO INC (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2025059685-A1 | METHODS FOR IN VIVO TARGETED DELIVERY OF A PAYLOAD | TAMBO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2024229427-A1 | TETRAZINE-BASED TARGETING AGENTS FOR IN VIVO DELIVERY OF A PAYLOAD | TAMBO, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| EP-4422696-A1 | TETRAZINE CONJUGATES FOR IN VIVO TARGETED DELIVERY OF A PAYLOAD | Tambo, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118369123-A | Tetrazine conjugates for in vivo targeted delivery of payloads | 坦博公司 | 2024-07-19 | — | — | CN | disclosed |
| WO-2024105234-A1 | DUAL INHIBITORS OF SIGMA-1 RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE AND THEIR USE IN THE TREATMENT OF PAIN | UNIVERSITAT DE BARCELONA (ES) | 2024-05-23 | — | — | WO | disclosed |
| CN-115141123-B | Compound, preparation method thereof and application thereof in preparation of dual inhibitors of histone deacetylase and epoxide hydrolase | 沈阳药科大学 | 2024-05-17 | — | — | CN | disclosed |
| US-20100249137-A1 | Novel sEH Inhibitors and Their Use | GlaxoSmithKline, LLC | 2010-09-30 | — | — | US | disclosed |
| US-20100210656-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210656-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| EP-2214487-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-08-11 | — | — | EP | disclosed |
| EP-2209376-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009049165-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049165-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049157-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049157-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249137-A1 | Novel sEH Inhibitors and Their Use | NCEH1, CTH, EPHX1 | TRPV4 3793/4885KIF11 4617/4885LOXL2 1869/4885 |
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | EPHX1, NCEH1, CYP46A1 | TRPV4 4764/4885KIF11 4552/4885LOXL2 3702/4885 |
| US-20250186592-A1 | TETRAZINE CONJUGATES FOR IN VIVO TARGETED DELIVERY OF A PAYLOAD | CD47, CD74, TIE1 | TRPV4 4697/4885KIF11 890/4885LOXL2 1164/4885 |
| US-20100210656-A1 | NOVEL sEH INHIBITORS AND THEIR USE | NCEH1, EPHX1, FAH | TRPV4 4717/4885KIF11 4445/4885LOXL2 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.